RT Journal Article
SR Electronic
T1 Treatment with Arbidol and Moxifloxacin in Ordinary and Severe Adult Patients Infected with COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.30.20117598
DO 10.1101/2020.05.30.20117598
A1 Wen-Na Xi
A1 Di Jin
A1 Ke Sun
A1 Rong-Yan Yu
A1 Xue-Bing Yao
A1 Biao-Shu Zou
A1 Zhi-Ying Song
A1 AO-Yu Yang
A1 Rui-Xia Luo
A1 Yun liu
A1 Yan-hua Li
A1 Shui-Lin Sun
A1 Dong-Shan Yu
YR 2020
UL http://medrxiv.org/content/early/2020/06/05/2020.05.30.20117598.abstract
AB Background An outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been widely spread. We aim to investigate the therapeutic effect of arbidol and moxifloxacin in patients infected with SARS-CoV-2.Methods We collected and analyzed data on 94 patients with COVID-19 including 27 severe patients at the Intensive Care Unit (ICU) and 74 ordinary patients at general isolation ward in Wuhan Xiehe Hospital, from February 15, 2020 to March 15, 2020. All patients were treated with arbidol (100mg each time, three times a day for 14 days) and moxifloxacin (0.4g each time, once a day for 7-14 days). Other data was also collected including demographic data, symptoms, laboratory findings, treatments and clinical outcomes.Results In basic characteristics, compared with the ordinary patients, the severe patients were older (median age was 63.0 years V.S 57.0 years, p=0.03), had higher proportion of hypertension (30% V.S 9%, p=0.03), higher possibility of getting fatigue and/or myalgia (26% V.S 6%, p=0.03), and had more obvious dyspnea symptom (26% V.S 3%, p=0.006). In regarding to laboratory results, we found the severe patients have higher white blood cell counts (p=0.003), neutrophil counts (p=0.007), higher levels of D-dimer (p<0.001), ALT (p<0.001) and AST (p=0.013) than the ordinary patients. After treatment of arbidol and moxifloxacin for one week, the rates of SARS-CoV-2 nucleic acid turning negative were 69.2% in the severe group and 77.8% in the ordinary group. A peculiar phenomenon was that IL-6 stands out among the cytokines in both groups, and higher in severe group than the ordinary one (p=0.011). After treating with arbidol and moxifloxacin for one week, IL-6 decreased significantly in severe group (p=0.023).Conclusion In summary, we proved the treatment of arbidol and moxifloxacin could be helpful in reducing viral load and inflammation during SARS-CoV2 infection, especially for negatively regulating fatal inflammation in severe COVID-19 patients. However, more evidence awaits further clinical verification.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe greatly acknowledge all the healthcare professionals who took care of the COVID-19 patients with their great effort, especially WN Xi and K Sun, who went to Wuhan Xiehe hospital to support the fight against the COVID-19 epidemic. Meanwhile, this work was supported by grants from the National Science and Technology Major Project for the Control and Prevention of Major Infectious Diseases in China (201811300954127).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below: Statement of ethics: as requested by Dr. Yu dongshan of our hospital, we conducted an ethical review of the subject "Treatment with Arbidol and Moxifloxacin in Ordinary and Severe Adult Patients Infected with COVID-19" according to the relevant management measures of clinical research. After the review by the medical research ethics committee, the study conforms to the ethical principles and the ethics committee agrees to conduct the study. The ethics committee will supervise the subject in accordance with the relevant national laws and regulations.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article.